Plenary Session - inactive due to federal service

In this bonus episode, we bring back Dr. Tom Beer of OHSU from episode 1.33 to discuss how to manage your personal finances. The interview is aimed at young physicians, but there is something for all audiences as we cover a broad range of topics: paying off loans, optimizing retirement savings, buying a home, and investing. Back us on Patreon! www.patreon.com/plenarysession

This week's episode begins with praise for the recent article by Booth CM, Karim S, and Mackillop WJ on real-world data published in Nature Reviews Clinical Oncology. Next, we tackle the resignation of Scott Gottlieb as FDA commissioner and how we can measure the success of the FDA. Finally, we have an interview with Dr. Deborah Cohen of OHSU on effective communication between the clinician and the patient and how we can use data from the Electronic Health Record to make meaningful improvements in care. Real-world data: doi.org/10.1038/s41571-019-0167-7 Back us on Patreon! www.patreon.com/plenarysession

This BONUS episode is the recording of a lecture given as part of the medical school class Appraising Medical Literature, taught at OHSU. This clip from the class critiques the recent JAMA Pediatrics paper "Association Between Screen Time and Children’s Performance on a Developmental Screening Test". Screen Time: doi.org/10.1001/jamapediatrics.2018.5056 Back us on Patreon! www.patreon.com/plenarysession

In this episode we discuss the controversy over the recent article in NEJM, "Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors", with Dr. Tom Deloughery of OHSU. We end with an interview with Dr. John McConnell, also of OHSU, on health economics and Medicaid. Andexanet Alfa: doi.org/10.1056/NEJMoa1814051 Back us on Patreon! www.patreon.com/plenarysession

In the first half of this episode, Dr. Sven Olson of OHSU joins us to help critique the recent NEJM paper, "Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura". In the second half, we interview Dr. Inmaculada Hernández of the University of Pittsburgh on her work on the economic principles behind runaway drug prices. Caplacizumab: doi.org/10.1056/NEJMoa1806311 Back us on Patreon! www.patreon.com/plenarysession

We feature two interviews this week: the first is a hallway conversation with [soon-to-be] Dr. Antonious Hazim of OHSU on the Declaration of Geneva and the second is a discussion with [soon-to-be] Dr. Joshua Niforatos on his recent paper in The American Journal of Emergency Medicine, titled "Financial relationships with industry among guideline authors for the management of acute ischemic stroke". Financial relationships: doi.org/10.1016/j.ajem.2019.01.037 Back us on Patreon! www.patreon.com/plenarysession

This episode features an interview with hematologist Dr. Thomas Deloughery of OHSU. We cover a broad range of topics including 23andMe, wilderness medicine, academia, and Twitter. We'll be back next week with our regular introductory monologue! Back us on Patreon! www.patreon.com/plenarysession

In this episode we interview Dr. Alex Denes of OHSU on his decades-long career in medicine: what practices have changed and what have stayed the same. No monologue this week - we'll be back next week with more insights! Back us on Patreon! www.patreon.com/plenarysession

In this episode we tackle Eli Lilly's drug Lartruvo (olaratumab) and the under-powered phase II trial that led to its FDA accelerated approval; a viewpoint in JAMA on new directions for cancer trials; and gene expression profiling for carcinoma of unknown primary. We end with an interview with Dr. Miriam Knoll of Hackensack Meridian Health on employment after residency or fellowship, residency training, and the medical specialty pipeline. Back us on Patreon! www.patreon.com/plenarysession

This BONUS episode is the recording of a talk given at the Salem City Club on January 11, 2019. It's the talk on medical reversal that has been featured in previous episodes, but this time the format and content have been updated for a broader, more general audience. Back us on Patreon! www.patreon.com/plenarysession

This week we dive into the recent paper by Drs. Cole and Dusetzina titled "Generic Price Competition For Specialty Drugs: Too Little, Too Late?". We also have an interview with Dr. Martin Schreiber of OHSU on his experiences as a trauma surgeon, both stateside and on the battlefield. Generic Price Competition: https://doi.org/10.1377/hlthaff.2017.1684 Back us on Patreon! www.patreon.com/plenarysession

This BONUS episode is the recording of a lecture given to the Bioethics Study Group at OHSU on January 9, 2019 on conflict of interest, specifically in the field of oncology. Backers of our Patreon will be sent accompanying slides. Back us on Patreon! www.patreon.com/plenarysession

In this episode, we discuss two recent papers published in the Journal of Clinical Oncology: ECOG-ACRIN 2511 and the update adding overall-survival and crossover results to KEYNOTE-024. We end with an interview with Dr. Joseph Shatzel of OHSU on mentorship. ECOG-ACRIN 2511: http://doi.org/10.1200/JCO.18.00264 KEYNOTE-024 update: http://doi.org/10.1200/JCO.18.00149 Back us on Patreon! www.patreon.com/plenarysession

In this episode we discuss guarantee-time bias in the context of the recent JAMA Oncology paper titled "Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer". We also have an interview with Dr. Tom Beer, the Deputy Director of the OHSU Knight Cancer Institute, on clinical trials, leadership, philanthropy, and future directions in cancer research. Profiling preexisting antibodies: doi.org/10.1001/jamaoncol.2018.5860 Back us on Patreon! www.patreon.com/plenarysession

Episode 1.32 ran a little long, so this is episode 1.32.1 - we broke out the interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado, to make the interview more accessible. Back us on Patreon! www.patreon.com/plenarysession

This week we discuss various academic indices including the h-index and the new Altmetric score, and we go over the recent NY Times article on conflict of interest. We end with an interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado. NY Times: https://www.nytimes.com/2018/12/31/upshot/congratulations-on-the-promotion-but-did-science-get-a-demotion.html Back us on Patreon! patreon.com/plenarysession

We begin this episode with a discussion of Dr. Mukherjee's ongoing study combining a ketogenic diet with PI3 kinase inhibition. We continue with a take on a recent reanalysis of COMET-1 and COMET-2, two failed randomized controlled trials of cabozantinib versus prednisone or mitoxantrone-prednisone in metastatic castration-resistant prostate cancer. We end with an interview on instabilities in the health insurance marketplace with Dr. Jane Zhu of OHSU, an expert in the Affordable Care Act. Keto diet + PI3 kinase: https://www.nytimes.com/2018/12/05/magazine/its-time-to-study-whether-eating-particular-diets-can-help-heal-us.html COMET-1: http://doi.org/10.1200/jco.2015.65.5597 COMET-2: https://doi.org/10.1016/j.eururo.2018.11.033 Back us on Patreon! https://www.patreon.com/plenarysession

This BONUS episode is the recording of a lecture given to the National Breast Cancer Coalition on December 11, 2018. It's on clinical trial endpoints, FDA drug approval, and incentives in oncology. Backers of our Patreon will be sent accompanying slides. Back us on Patreon! www.patreon.com/plenarysession

We begin this episode with a critique of the recent paper in the BMJ, "Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial" and we end it with an interview with Dr. Andre Mansoor, discussing his new book: "Frameworks for Internal Medicine." Parachutes: https://www.bmj.com/content/363/bmj.k5094 Back us on Patreon! https://www.patreon.com/plenarysession

In this episode we critique two recent FDA drug approvals (venetoclax in combination with azacitidine or decitabine or low-dose cytarabine; glasdegib in combination with low-dose cytarabine -- both for acute myeloid leukemia)and we interview Dr. Chadi Nabhan, the Chief Medical Officer of Cardinal Health, on career transitions. The interview was taped on location at the 2018 annual conference of the American Society of Hematology in San Diego.

This BONUS episode is the recording of a lecture given to hospitalists at Kaiser Permanente on November 14, 2018. It's a slightly different version of the talk on medical reversals that we recorded for episode 1.16. Backers of our Patreon will be sent accompanying slides. Back us on Patreon: https://www.patreon.com/plenarysession

Having just returned from the 2018 American Society of Hematology (ASH) Annual Meeting, we begin this episode by discussing the abstract of a study that stretches its conclusions. We dedicate most of the episode to an interview with Dr. Sima Desai, the program director for OHSU's Internal Medicine Residency Program. She gives some great insight on the program's inner workings. ASH abstract: https://ash.confex.com/ash/2018/webprogram/Paper117448.html We have also launched our Patreon page! Become a patron at www.patreon.com/plenarysession.

In this episode we discuss: Dr. Gilbert Welch's Wikipedia page and how we should keep his decades of work in perspective, a Twitter conversation between experts on differing interpretations of results from next-generation sequencing, the new paper in JAMA titled "Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications", and finally, along with Dr. Sam Edwards of OHSU, we criticize the recent perspective piece in NEJM titled "Beyond Evidence-Based Medicine". Welch's Wikipedia: https://en.wikipedia.org/wiki/H._Gilbert_Welch Pregabalin: doi.org/10.1001/jamainternmed.2018.5705 Beyond EBM: doi.org/10.1056/NEJMp1806984 We have also launched our Patreon page! Become a patron at https://www.patreon.com/plenarysession.

In this episode we discuss John Ioannidis' article on the uselessness of medical conferences, published in JAMA: "Are Medical Conferences Useful? And for Whom?", followed by an interview with return-guest Dr. Adam Obley on a few recent clinical trials: Vascepa, fish oil, vitamin D, and methotrexate. Medical conferences: doi.org/10.1001/jama.2012.360

This BONUS episode is the recording of a lecture given as part of the Biomedical Engineering Seminar series at Oregon Health & Science University on November 9, 2018. The talk is on how to move technological devices to the clinic with fewer reversals.

In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency. Elo-pom-dex: http://doi.org/10.1056/NEJMoa1805762 Immunotherapy combinations: http://doi.org/10.1056/NEJMp1803602 9 weeks that matter: http://doi.org/10.1016/S1470-2045(18)30752-6 Dr. Turner's seminal paper: https://doi.org/10.1056/NEJMsa065779

In this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall survival results from PALOMA-3, discuss Dr. Gyawali et al.'s paper on the need for transparency in reporting harms from cancer drugs, and interview Dr. Talal Hilal from the Scottsdale Mayo Clinic on his advice for trainees. Nab-paclitaxel and gemcitabine: doi.org/10.1001/jamaoncol.2018.3277 Palbociclib and fulvestrant: doi.org/10.1056/NEJMoa1810527 Reporting harms: doi.org/10.1136/bmj.k4383

We begin this episode analyzing the unrepentant hype of precision oncology in a monologue that was originally one half of a debate titled: "Is Precision Oncology Generating Patient Benefit or Just Hype?" We conclude with an interview with Dr. Andrae Vandross on the mentor/mentee relationship.

This BONUS episode is the recording of a lecture given as part of a Cancer Intersession course for med students at Oregon Health & Science University on October 25, 2018. The talk is an introduction to cancer drug policy.

In this episode we evaluate the IMpassion130 trial on the use of atezolizumab in triple-negative breast cancer. We also interview Dr. Brian Chan of OHSU on a randomized controlled trial he's running that tests whether Dr. Gawande's idea of "hot-spotting" -- tailoring interventions to medically complex patients -- does decrease hospitalizations. IMpassion130: doi.org/10.1056/NEJMoa1809615 Hot-spotting: https://www.newyorker.com/magazine/2011/01/24/the-hot-spotters

This BONUS episode is the recording of a two-part talk addressed to oncology fellows given at Oregon Health & Science University on October 5 and October 12, 2018. The talk is on how to interpret cancer clinical trials.

This BONUS episode is the recording of the Hospitalist Grand Rounds given at Oregon Health & Science University on October 11, 2018. The talk is on medical reversal. Before the talk we discuss the paper "Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results" by Silberzahn et al., published in Advances in Methods and Practices in Psychological Science. Paper: doi.org/10.1177/2515245917747646

In this episode we review the recent paper in Nature Reviews Clinical Oncology by Booth, C.M. and Detsky, A.S. titled "Why patients receive treatments that are minimally effective?". We discuss the failure of CheckMate 331 to meet its primary endpoint despite having received accelerated FDA approval. Finally, we bring back Dr. Adam Obley (from episode 1.01) to talk about low-value healthcare, medical education, social media, and more!

This BONUS episode is the recording of the 22nd annual Pennington Lecture given at Oregon Health & Science University on September 21, 2018. The lecture is on seven myths of medicine and marketing. Before the lecture we read and discuss the editorial "Desperation Oncology" by Tito Fojo, published in Seminars in Oncology.

Listen in for a breakdown of the good and the bad of KEYNOTE-189(trial published in NEJM), a discussion with Dr. Talal Hilal of the Mayo Clinic on the rise of minimal residual disease as a clinical endpoint, and an interview with Dr. Adam Cifu of the University of Chicago Pritzker School of Medicine on medical education, sham trials, and more.

This BONUS episode is the recording of a Grand Rounds talk given at Oregon Health & Science University on September 19, 2018. The talk was inspired by the article by JPA Ioannidis titled "Evidence-based medicine has been hijacked: a report to David Sackett", published May 2016 in the Journal of Clinical Epidemiology.

We discuss Dr. Califf's comment on the "social media peanut gallery of experts", Dr. Drazen's comment on "research parasites" and his retirement from NEJM, the recent paper in JAMA on long-term follow up for antibiotics as compared to appendectomies, and the paper in JAMA Internal Medicine on the relationship between health-related quality of life and progression-free survival. Finally, we interview Dr. Bishal Gyawali on a variety of topics, including cancer groundshot.

Today we tackle some cardiologists' opposition to criticizing clinical trials on Twitter, the PACIFIC trial on durvalumab in stage III non–small-cell lung cancer, and the recent paper in Heart: "Percutaneous Coronary Intervention for Stable Coronary Artery Disease" by R.K. Al-Lamee, A.N. Nowbar, and D.P. Francis. We end with an interview on academic medical publishing with Dr. Rebecca Cooney, North American Executive Editor of The Lancet.

Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.

In this episode we discuss hyperprolific authors and the recent comment in Nature by JPA Ioannidis, R Klavans, & KW Boyack; NCCN guidelines with fourth-year medical student Jeffrey Wagner; and point-of-care ultrasounds with Dr. Renee Dversdal of OHSU.

In this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview cardiologist Dr. John Mandrola on new directions forward for evidence-based medicine.

In this episode we break down the RELEVANCE trial published in the New England Journal of Medicine; discuss big data in observational studies with Jenny Gill, MS; and interview Dr. Catherine Livingston of OHSU, an expert in healthcare policy, on her work with the Oregon Health Authority and state Medicaid.

In this episode we cover the cost and efficacy of cancer drugs; review ECHELON-1; interview Dr. Derrick Tao of OHSU about his recent Lancet Oncology paper on poor control arms; and discuss evidence-based medicine with EBM expert and internist at OHSU, Dr. Martha Gerrity.

This week's episode is on nutritional epidemiology by JPA Ioannidis; lenvatinib for hepatocellular carcinoma; nivolumab and ipilimumab for melanoma; and #medtwitter with Dr. Avi O Glasser from OHSU.

We're moving to our new format. We begin with a monologue of the most noteworthy articles in this week's news. We'll be talking about real-world evidence, Right to Try, talazoparib, and the FDA approval for nivolumab in small-cell lung cancer. In the second half of the show, we'll interview Dr. Andrae Vandross, a community oncologist at UCLA Medical Center.

In episode 2, we discuss the fellowship program and then take a deep dive into hype surrounding cancer drugs. Our guest is Jeremy Cetnar, MD from Oregon Health & Science University.

Join us for an introduction to who we are and what our podcast is about, then stick around for a hard-hitting discussion of evidence-based medicine, randomized controlled trials, sham controls, and broad next-generation sequencing in cancer. Our guest is Adam Obley, an Assistant Professor of Medicine at Oregon Health & Science University.